AstraZeneca stock rises after Enhertu access win in England
AstraZeneca’s shares rose after Reuters reported England’s NHS reversed an earlier cost-effectiveness rejection for Enhertu.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.